切换至 "中华医学电子期刊资源库"

中华临床医师杂志(电子版) ›› 2018, Vol. 12 ›› Issue (03) : 181 -184. doi: 10.3877/cma.j.issn.1674-0785.2018.03.013

所属专题: 文献

综述

CT引导下125I放射性粒子植入术在不可切除胰腺癌治疗中的应用现状及展望
吴维霞1, 周志刚1,(), 邢明泉2   
  1. 1. 450000 郑州大学第一附属医院放射科
    2. 046000 山西长治,长治医学院
  • 收稿日期:2017-09-10 出版日期:2018-02-01
  • 通信作者: 周志刚

Application and prospect of CT-guided 125I radioactive particle implantation in treatment of unresectable pancreatic cancer

Weixia Wu1, Zhigang Zhou1,(), Mingquan Xing2   

  1. 1. Radiology Department, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450000, China
    2. Changzhi Medical College, Changzhi 046000, China
  • Received:2017-09-10 Published:2018-02-01
  • Corresponding author: Zhigang Zhou
  • About author:
    Corresponding author: Zhou Zhigang, Email:
引用本文:

吴维霞, 周志刚, 邢明泉. CT引导下125I放射性粒子植入术在不可切除胰腺癌治疗中的应用现状及展望[J/OL]. 中华临床医师杂志(电子版), 2018, 12(03): 181-184.

Weixia Wu, Zhigang Zhou, Mingquan Xing. Application and prospect of CT-guided 125I radioactive particle implantation in treatment of unresectable pancreatic cancer[J/OL]. Chinese Journal of Clinicians(Electronic Edition), 2018, 12(03): 181-184.

近年来,125I放射性粒子治疗不可切除胰腺癌的治疗方法,由于其具有能有效的控制肿瘤生长,缓解患者疼痛,延长患者生存期等优势,在很大程度上改善着中晚期胰腺癌患者的生存率和生活质量。CT引导下125I放射性粒子植入治疗不可切除胰腺癌的临床研究不断增多,而以三维打印模板制定个体化理想合理的治疗计划系统的模式在粒子剂量选择上的应用成为研究的热点和难点,现对此方面的研究进展作一综述,期待为临床推广提供方向。

In recent years, 125I radioactive particle implantation has significantly improved the survival rate and quality of life in patients with unresectable pancreatic cancer, because it can effectively control tumor growth, relieve the pain of patients, and prolong the survival time of the patients. The clinical research of CT-guided 125I radioactive particle implantation for the treatment of unresectable pancreatic cancer has greatly increased, and the application of 3D printing template-based individualized treatment planning system has become a hot topic, although particle dose selection is still a challenge. In this paper, we review the progress of CT-guided 125I radioactive particle implantation in the treatment of unresectable pancreatic cancer, with an aim to promote its future clinical application.

[1]
张喆,金成兵,周崑, 等. 无法手术的中晚期胰腺癌HIFU治疗后的生存分析 [J]. 重庆医学, 2017, 16(64): 2190-2192.
[2]
Li X, Ma G, Ma Q, et al. Neurotransmitter substance P mediates pancreatic cancer perineural invasion via NK-1R in cancer cells [J]. Mol Cancer Res, 2013, 11(3): 294-302.
[3]
胡琰琰,于晓玲. 放射性粒子植入技术治疗胰腺癌的临床研究进展 [J]. 解放军医学院学报, 2017, 38(5): 475-477.
[4]
Du YQ, Li ZS, Jin ZD. Endoscope-assisted brachytherapy for pancreatic cancer: From tumor killing to pain relief and drainage [J]. J Interv Gastroenterol, 2011, 1(1): 23-27.
[5]
盖宝东,舒振波,丁大勇, 等. 125I放射性粒子治疗胰腺癌 [J]. 中国普外基础与临床杂志, 2007, 14(5): 582-583.
[6]
Peretz T, Nori D, Hilaris B, et al. Treatment of primary unresectable carcinoma of the pancreas with I-125 implantation [J]. Int J Radiat Oncol Biol Phys, 1989, 17(5): 931-935.
[7]
Parashar B, Arora S, Wernicke AG. Radiation therapy for early stage lung cancer [J]. Semin Intervent Radiol, 2013, 30(2): 185-190.
[8]
Yang M, Fang Z, Yan Z, et al. Transarterial chemoembolisa-tion (TACE) combined with endovascular implantation of an iodine-125 seed strand for the treatment of hepatocellular carcinoma with portal vein tumour thrombosis versus TACE a-lone: a two-arm, randomised clinical trial [J]. J Cancer Res Clin Oncol, 2014, 140(2): 211-219.
[9]
张颖,林琦,袁苑, 等. 3D打印个体化模板联合CT引导125I粒子植入治疗胸壁转移瘤1例 [J]. 山东大学学报(医学版), 2016, 4(56): 94-96.
[10]
Jiang P, Liu C, Wang J, et al. Computed tomography (CT) -guided interstitial permanent implantation of (125) I seeds for refractory chest wall metastasis or recurrence [J]. Technol Cancer Res Treat, 2015, 14(1) :11-18.
[11]
Ji B, Zhang W, Liu S, et al. Comparison of iodine-125 seed implantation and pancreaticoduodenectomy in the treatment of pancreatic cancer [J]. Int J Med Sci, 2014, 11(9): 893-896.
[12]
Liu B, Zhou T, Geng J, et al. Percutaneous computed tomography-guided iodine-125 seeds implantation for unresectable pancreatic cancer [J]. Indian J Cancer, 2015, 52(Suppl 2): e69-e74.
[13]
Zhongmin W, Yu L, Fenju L, et al. Clinical efficacy of CT-guided iodine-125 seed implantation therapy in patients with advanced pancreatic cancer [J]. Eur Radiol, 2010, 20(7): 1786-1791.
[14]
伦俊杰,赵俊玲,孙建业, 等. CT引导下125I放射性粒子植入联合化疗对中晚期胰腺癌的疗效 [J]. 介入放射学杂志, 2015, 24(6): 494-497.
[15]
张杰,周志刚,吕绍娟, 等. CT导向下放射性粒子125I联合化学粒子中人氟安治疗胰腺癌 [J]. 医学信息, 2009, 22(12): 1133-1134.
[16]
李帅,周志刚,高剑波, 等. CT引导下组织间植入125I粒子联合替吉奥治疗老年胰腺癌疗效分析 [J]. 郑州大学学报(医学版), 2015, 50(2): 270-273.
[17]
Chen Y, Wang XL, Yan ZP, et al. Damage to pig bile duct caused by intraluminal brachytherapy using a (125)I ribbon [J]. Acta Radiol, 2013, 54(3): 272-277.
[18]
Zhu HD, Guo JH, Zhu GY, et al. A novel biliary stent loaded with (125)I seeds in patients with malignant biliary obstruction: Preliminary results versus a conventional biliary stent [J]. J Hepatol, 2012, 56(5): 1104-1111.
[19]
Yang M, Yan Z, Luo J, et al. A pilot study of intraluminal brachytherapy using (125)I seed strand for locally advanced pancreatic ductal adenocarcinoma with obstructive jaundice [J]. Brachytherapy, 2016, 15(6): 859-864.
[20]
Urzua U, Tapta V, Geraldo MP, et al. Nerve growth factor stimulates cellular proliferation of human epithelial ovarian cancer [J]. Horm Metab Res, 2012, 44(9): 656-661.
[21]
Xu JB, Yang XC, Guo JH, et al. Serum nerve growth factor level indicates therapeutic efficacy of 125I seed implantation in advanced pancreatic adenocarcinoma [J]. Eur Rev Med Pharmacol Sci, 2015, 19(18): 3385-3390.
[22]
张颖,林琦,韩明勇, 等. 3D打印个体化模板联合CT引导125I粒子植入治疗恶性肿瘤质量评价 [J]. 山东大学学报(医学版), 2016, 54(11): 44-50.
[23]
张宏涛,底学敏,于慧敏, 等. 3D打印模板引导125I粒子植入术前术后剂量对比 [J]. 中华医学杂志, 2016, 96(9): 712-715.
[24]
姜玉良,王皓,吉喆, 等. CT引导辅助3D打印个体化非共面模板指导125I粒子治疗盆腔复发肿瘤剂量学研究 [J]. 中华放射肿瘤学杂志, 2016, 25(9): 959-964.
[25]
Ikushima H. Radiation therapy: state of the art and the future [J]. J Med Invest, 2010, 57(1-2): 1-11.
[26]
申文江. 放射性粒子植入的创新性临床研究 [J]. 山东大学学报(医学版), 2017, 55(2): 1-3.
[27]
Stewart A, Parashar B, Patel M, et al. American brachy-therapy society consensus guidelines for thoracic brachythe-rapy for lung cancer [J]. Brachytherapy, 2016, 15(1): 1-11.
[28]
Kovtun KA, Wolfsberger L, Niedermayr T, et al. Dosi-metric quality and evolution of edema after low -dose-ratebrachytherapy for small prostates: Implications for the use of newer isotopes [J]. Brachytherapy, 2014, 13(2): 152-156.
[29]
Marcu LG, Lawson JM. Technical and dosimetric as-pects of iodine-125 seed reimplantation in suboptimalprostate implants [J]. Br J Radiol, 2013, 86(1026): 20130058.
[30]
Huang MW, Liu SM, Zhang JG. A digital model indi-vidual template and CT-guided 125I seed implants for ma-lignant tumors of the head and neck [J]. J Radiat Res, 2012, 53(6): 973-977.
[31]
Keyes M, Morris WJ, Spadinger I, et al. Radiation on-cology and medical physicists quality assurance in british columbia cancer agency provincial prostate brachyther-apy program [J]. Brachytherapy, 2013, 12(4): 343-355.
[32]
Zhang HT, Di XM, Yu HM, et al. Dose comparison betw een pre and post operation of 125I seeds implantation guided by 3D print template [J]. Zhonghua Yi Xue Za Zhi, 2016, 96(9): 712-715.
[33]
Wang ZM, Lu J, Zhang LY, et al. Biological effects of low-dose-rate irradiation of pancreatic carcinoma cells in vitro u-sing 125I seeds [J]. World J Gastroenterol, 2015, 21(8): 2336-2342.
[34]
Zhang Y, Lin Q, Han MY, et al. The feasibility of 3D print individual template combination with CT guided iodine-125 seed implantation for malig-nancy [J]. J Shandong University (Health Science), 2016, 54(11): 44-50.
[35]
Feng S, Wang L, Xiao Z, et al. 125I seed implant brachy-therapy for painful bone metastases after failure of externalbeam radiation therapy [J]. Medicine, 2015, 94(31): e1253.
[36]
Andren-Sandberg A. Pancreatic cancer: chemotherapy and radiotherapy [J]. N Am J Med Sci, 2011, 3(1): 1-12.
[37]
姜玉良. 北京大学第三医院完成首例CT引导联合3D打印模板指导放射性粒子植入治疗腹膜后复发肿瘤 [J]. 北京大学学报(医学版), 2016, 48(1): 182.
[1] 尚培中, 张润萍, 张伟, 贾国洪, 李晓武, 苗建军, 刘冰. 梗阻性黄疸临床防治新技术单中心应用研究[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(01): 104-107.
[2] 张柯迪, 潘立超, 张卓超, 王斐, 尹注增. 高危复发可切除胰腺癌新辅助治疗后机器人胰体尾癌根治术[J/OL]. 中华腔镜外科杂志(电子版), 2023, 16(03): 175-178.
[3] 王勤运, 许大彬, 张恩犁, 钱海, 赵之明. 完全脏器转位机器人胰十二指肠切除术一例[J/OL]. 中华腔镜外科杂志(电子版), 2023, 16(01): 52-55.
[4] 李新雄, 张再重, 赵虎, 肖春红, 王烈. 作为胰腺癌生物标志物的外泌体内容物研究进展[J/OL]. 中华细胞与干细胞杂志(电子版), 2023, 13(01): 53-57.
[5] 张瑜, 姜梦妮. 基于DWI信号值构建局部进展期胰腺癌放化疗生存获益预测模型[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(05): 657-664.
[6] 孟煜凡, 李永政, 樊知遥, 展翰翔. 瘤内微生物在胰腺癌发病和演进中的作用机制及研究进展[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(04): 577-582.
[7] 王天福, 王刚. 自身免疫性胰腺炎诊治现状[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(04): 492-497.
[8] 黄金灿, 王迪, 崔松平, 陈晴, 吕少诚, 贺强, 郎韧. 预后营养指数对交界可切除胰腺癌患者术后预后的预测价值[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(01): 51-56.
[9] 段伟, 刘飞, 许光源, 程宇豪, 陈星. 食管癌调强放疗计划剂量学参数差异对放射性肺炎发生及严重程度的影响[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(04): 320-324.
[10] 楚海强, 杨远游, 任刚. 胰腺癌放射治疗联合其他治疗方法的研究进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(04): 392-396.
[11] 曹文玺, 陈箫, 竺来法, 周永平. 尼妥珠单抗联合白蛋白结合型紫杉醇治疗胰腺癌的有效性及安全性分析[J/OL]. 中华临床医师杂志(电子版), 2023, 17(04): 409-413.
[12] 任刚, 沈光凯, 王颖杰. 胰腺癌消融放疗的研究进展[J/OL]. 中华临床医师杂志(电子版), 2022, 16(12): 1276-1279.
[13] 任刚, 沈光凯, 宋佳钊, 李晶, 王勇, 王颖杰. 高剂量少分次放疗对胰腺癌患者免疫功能、营养及体力状态的影响[J/OL]. 中华临床医师杂志(电子版), 2022, 16(09): 876-880.
[14] 陈升鑫, 翟亚奇, 卜保国, 陈德鑫, 吴浪, 方开萱, 刘文静, 李明阳, 令狐恩强. 自身免疫性胰腺炎临床特征分析[J/OL]. 中华胃肠内镜电子杂志, 2023, 10(01): 46-51.
[15] 吴子龙, 吴冰, 袁开盛, 胡瑞翔, 杨华, 王存川. 肥胖与胰腺疾病研究进展[J/OL]. 中华肥胖与代谢病电子杂志, 2024, 10(03): 213-219.
阅读次数
全文


摘要